Carl Zeiss Meditec looks back on successful financial year
(Thomson Reuters ONE) -
Carl Zeiss Meditec AG /
Carl Zeiss Meditec looks back on successful financial year
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Above average increase in EBIT/positive development in all strategic business
units and reporting regions
JENA, 6 December 2012
Medical technology company Carl Zeiss Meditec AG continued its growth trend in
financial year 2011/2012. Revenue climbed 13.6 percent to EUR 861.9 million and
thus slightly exceeded the upper limit of the revenue forecast. Earnings before
interest and tax (EBIT) rose by 18.7 percent year-on-year, to EUR 122.9 million.
All regions and strategic business units contributed to this growth.
With double-digit growth rates in revenue and its operating result, Carl Zeiss
Meditec once again grew significantly in the past financial year (ending:
30 September 2012). The medical technology company even slightly exceeded its
revenue forecast for financial year 2011/2012, of EUR 830 - 860 million, with
revenue growth of 13.6 percent to EUR 861.9 million (previous year: EUR 758.8
million). In addition to increasing its earnings before interest and tax (EBIT)
by 18.7 percent to EUR 122.9 million (previous year: EUR 103.6 million), Carl
Zeiss Meditec also further increased its profitability: the EBIT margin rose to
14.3 percent, compared with 13.6 percent the previous year. Earnings per share
increased to EUR 0.88 (previous year: EUR 0.82). Cash flow from operating
activities rose to EUR 92.1 million (previous year: EUR 33.2 million). As
announced, the Supervisory Board and Management Board shall propose to the
Annual General Meeting a dividend of EUR 0.40 per share for financial year
2011/2012.
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, gave his take on
the positive figures: "We are very pleased with the development of revenue and
earnings. In spite of sometimes challenging conditions in the global economy, we
achieved growth in all strategic business units (SBUs) and regions."
Profitability continuously improved. "By investing in new products and sales
channels we are also simultaneously laying the foundations to make our growth
sustainably positive," said Monz. Carl Zeiss Meditec is well on its way to
achieving its EBIT margin target of 15 percent by 2015. "Carl Zeiss Meditec is
strategically on target. The well balanced regional distribution of our
revenues, which reflects the growing importance of the Asian growth markets,
stabilizes our business. The expansion of our service activities and recurring
revenue make us less exposed to the typically greater fluctuations in the
capital assets business."
The proportion of employees working in our Research and Development (R&D)
department, on the innovations of the future, remains high at around
16 percent. In the reporting year Carl Zeiss Meditec invested 10.8 percent of
its revenue in R&D.
Revenue by business unit
As in the past few quarters, development in the Microsurgery SBU was markedly
positive across all product groups, with total growth of 17.8 percent in the
financial year. There was particularly strong demand for surgical microscopes
from the field of neuro/ENT surgery. The growth of 17.5 percent in the SBU
Surgical Ophthalmology was particularly attributable, once again, to the high
demand for intraocular lenses for minimally invasive cataract surgery and the
integration of a distribution acquisition in Spain. The growth in the SBU
Ophthalmic Systems was driven in particular by a growing demand for innovative
lasers for the refractive correction of vision defects. This SBU's revenue grew
by 8.7 percent compared with the previous year.
Revenue by region
With some regional differences, the development of revenue in the EMEA region
(Europe, Middle East and Africa) was positive overall. In an unstable market
environment, revenue here increased by 11.0 percent: as a result of stable
growth in the core markets and a significant increase in revenue in Russia and
the Middle East, individual declines in Southern Europe were considerably
overcompensated. In the Americas region, the double-digit increase in revenue by
14.2 percent was comparatively higher, which is attributable to a persistently
strong demand from the USA, the largest market by far, as well as to encouraging
contributions to growth from Latin America. The Asia/Pacific region continues to
hold considerable potential for growth. Revenue in this region increased by
15.8 percent.
Outlook
According to the company's estimates, a growing demand for medical products can
be anticipated due to the demographic trend. Current global economic
development, on the other hand, is characterized by uncertainties that make a
forecast difficult. The objective remains to grow at least as fast as the
industry in the markets and regions in which the company operates. Ludwin Monz:
"We shall also continue to benefit from our substantial investments in research
and development."
Revenue by strategic business unit
+------------------------+-----------+-----------+---------------------------+
| Figures in EUR '000 | FY | FY | Change from previous year |
| | | | |
| | 2010/2011 | 2011/2012 | |
+------------------------+-----------+-----------+---------------------------+
| Ophthalmic Systems | 345,972 | 375,909 | + 8.7% |
+------------------------+-----------+-----------+---------------------------+
| Surgical Ophthalmology | 91,667 | 107,741 | + 17.5% |
+------------------------+-----------+-----------+---------------------------+
| Microsurgery | 321,160 | 378,225 | + 17.8% |
+------------------------+-----------+-----------+---------------------------+
Revenue by region
+---------------------+-----------+-----------+---------------------------+
| Figures in EUR '000 | FY | FY | Change from previous year |
| | | | |
| | 2010/2011 | 2011/2012 | |
+---------------------+-----------+-----------+---------------------------+
| EMEA | 261,786 | 290,500 | + 11.0% |
+---------------------+-----------+-----------+---------------------------+
| Americas | 265,964 | 303,853 | + 14.2% |
+---------------------+-----------+-----------+---------------------------+
| Asia/Pacific region | 231,043 | 267,522 | + 15.8% |
+---------------------+-----------+-----------+---------------------------+
Press contacts:
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG
Phone+49 (0)3641 220-331, E-Mail: press(at)meditec.zeiss.com
Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec AG
Phone +49 (0)3641 220-106, E-Mail: investors(at)meditec.zeiss.com
www.meditec.zeiss.com/press
Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the
German stock exchange, is one of the world's leading medical technology
companies. The company supplies innovative technologies and application-oriented
solutions designed to help doctors improve the quality of life of their
patients. It provides complete packages of solutions for the diagnosis and
treatment of eye diseases, including implants and consumable materials. The
company creates innovative visualization solutions in the field of microsurgery.
The medical technology portfolio of Carl Zeiss Meditec is rounded off by
promising, future-oriented technologies such as intraoperative radiotherapy. In
financial year 2011/2012 (ended 30 September) the Group's more than 2,400
employees generated revenue of almost ? 862 million.
The head office of Carl Zeiss Meditec is in Jena, Germany. The company has
subsidiaries in Germany and abroad; more than 50 percent of its employees are
based in the USA, Japan, Spain and France. The Center for Research and
Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center
for Research and Development in Shanghai, China, strengthen the company's
presence in these rapidly developing economies. Around 35 percent of Carl Zeiss
Meditec shares are in free float. The remaining approx. 65 percent are held by
Carl Zeiss AG, one of the world's leading groups in the optical and
optoelectronic industries.
Carl Zeiss offers innovative solutions for the future-oriented markets of
Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle
Products. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss
Foundation.
For more information visit: www.meditec.zeiss.de
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
[HUG#1662999]
Unternehmensinformation / Kurzprofil:
Datum: 06.12.2012 - 07:01 Uhr
Sprache: Deutsch
News-ID 210174
Anzahl Zeichen: 10329
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec looks back on successful financial year"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
